Co-Diagnostics Announces Private Placement Agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 20 2026
0mins
Source: seekingalpha
- Financing Size: Co-Diagnostics has entered into a private placement agreement with institutional investors to sell 1.65 million shares and pre-funded warrants, with gross proceeds estimated at approximately $3 million, indicating strong market confidence in its future growth.
- Warrant Details: The accompanying warrants allow for the purchase of up to 3.29 million additional shares at an exercise price of $1.571 per share, which are immediately exercisable and expire in five years, enhancing potential returns for investors.
- Market Reaction: Following the announcement of the financing, Co-Diagnostics' stock price surged about 11% during after-market trading on Tuesday, reflecting optimistic sentiment among investors regarding the company's prospects, which may further boost its market performance.
- Future Outlook: Co-Diagnostics anticipates filing for FDA 510(k) approval in the third quarter, as CoSara expands its total addressable market to approximately $13 billion, significantly enhancing the company's growth potential and competitive position in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CODX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CODX
Wall Street analysts forecast CODX stock price to fall
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 7.300
Low
1.50
Averages
1.50
High
1.50
Current: 7.300
Low
1.50
Averages
1.50
High
1.50
About CODX
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Joint Development Strategy: Co-Diagnostics has partnered with CoSara Diagnostics to advance a PCR testing strategy for the Bundibugyo virus, aiming to rapidly address the Ebola outbreak in the Democratic Republic of the Congo and Uganda, which is expected to enhance the international community's response capabilities.
- Enhanced Response Capacity: The World Health Organization reports over 900 suspected cases and 220 suspected deaths from the Ebola outbreak, indicating that Co-Diagnostics' testing strategy will help meet the increasing public health demands in the affected regions.
- Technology Platform Evaluation: The company is evaluating assay configurations for multiple ebolavirus species and plans to support point-of-care and decentralized testing environments, thereby enhancing the adaptability and competitiveness of its PCR platform in the market.
- Regulatory Review Process: Co-Diagnostics' PCR platform is currently under review by the FDA and other regulatory bodies, and it is not yet available for sale; future regulatory approvals will directly impact its market launch and commercialization efforts.
See More
- Significant Pre-Market Gains: Wellgistics Health, Inc. (WGRX) surged 29% to $4.05 in pre-market trading, indicating strong market confidence in its future growth, which may attract more investor interest.
- Other Gainers: Co-Diagnostics, Inc. (CODX) rose 11% to $8.12, while Palladyne AI Corp. (PDYN) increased 10% to $8.21, reflecting an overall positive sentiment in the biotech sector that could drive investment momentum.
- Pre-Market Decliners: AIM ImmunoTech Inc. (AIM) fell 21% to $0.32, highlighting market concerns about its outlook, which may lead investors to reassess their strategies.
- Additional Decliners: BioRestorative Therapies, Inc. (BRTX) dropped 20% to $1.30, and Aditxt, Inc. (ADTX) decreased 18% to $0.17, indicating a lack of confidence in certain biotech companies, potentially impacting their fundraising capabilities.
See More
- CODX Stock Surge: Co-Diagnostics Inc. (CODX) saw its stock price jump nearly 80% to $9.11 on Tuesday as it advances the development of its Ebola PCR assay, which is expected to significantly enhance the company's competitiveness in the molecular diagnostics market.
- NRXP Regulatory Catalysts: NRx Pharmaceuticals Inc. (NRXP) shares rose over 30% to $4.31, driven by the anticipation of a New Drug Application submission to the FDA, which is expected to boost the company's market share in the treatment of suicidal depression.
- ECOR Revenue Growth: electroCore Inc. (ECOR) reported a 43% revenue increase in Q1, with expectations of a 30% rise in annual revenue compared to 2025, leading to a 33.58% stock price increase, indicating strong performance in the bioelectronic medicine sector.
- OTLK Regulatory Progress: Outlook Therapeutics Inc. (OTLK) shares jumped over 29% to $0.40 following positive regulatory developments regarding LYTENAVA, with plans to resubmit the Biologics License Application in June 2026, reflecting a strategic shift in their approach to FDA engagement.
See More
- Market Recovery: The S&P 500 rose 0.6% to close at 7,519.12, while the Nasdaq gained 1.2% to 26,656.18, indicating increased investor confidence in U.S. equities, particularly amid positive developments in peace talks with Iran.
- Small-Cap Surge: The Russell 2000 index climbed 1.8% to reach a record high, marking its fourth consecutive day of gains, reflecting optimistic sentiment towards small-cap stocks likely driven by expectations of economic recovery.
- Tech Stocks Lead Gains: Micron Technology's stock surged after UBS raised its price target to $1,625, significantly boosting overall tech sector performance and reinforcing strong investor confidence in the technology industry.
- Oil Market Volatility: Despite military exchanges between the U.S. and Iran raising concerns, West Texas Intermediate crude futures fell 2.81% to $93.89 per barrel, while Brent crude rose 3.58% to $99.58, illustrating the market's complex reactions to energy prices.
See More
- Stock Surge: Co-Diagnostics (CODX) shares soared nearly 80% on Tuesday, extending a blistering six-session rally that has seen the stock rise over 630%, reflecting strong market demand for diagnostics amid growing Ebola outbreak concerns.
- International Deployment Plan: The company is collaborating with its Indian joint venture, CoSara Diagnostics, to expedite international deployment in response to the potential global spread of the Ebola outbreak, highlighting its proactive role in emergency response efforts.
- Testing Technology Development: Co-Diagnostics is developing a PCR test targeting the Bundibugyo virus strain, with plans to introduce both Bundibugyo-specific and pan-Ebola test configurations to enhance monitoring capabilities for the outbreak.
- Global Health Emergency: The World Health Organization has declared the outbreak a public health emergency of international concern, with over 900 suspected cases and 223 suspected deaths reported, underscoring the severity of the situation and its threat to global health.
See More











